Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Nat Med. Author manuscript; available in PMC 2013 March 30.
Published in final edited form as:
Published online 2012 September 30. doi:  10.1038/nm.2963
PMCID: PMC3466346

Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity


The ability of the human immune system to respond to vaccination declines with age. We identified an age-associated defect in T cell receptor (TCR)-induced ERK phosphorylation in naïve CD4+ T cells (P<0.0001) while other signals, such as ZAP70 and PLC-γ1 phosphorylation were not impaired. The defective ERK signaling was caused by the dual specific phosphatase (DUSP) 6 whose protein levels increased with age (r = 0.68, P < 0.0001) due to a decline in repression by miR-181a (r = −0.59, P < 0.0001). Reconstitution of miR-181a lowered DUSP6 levels in naïve CD4+ T cells in elderly individuals. DUSP6 repression with miR-181a or specific siRNA, and DUSP6 inhibition with the allosteric inhibitor (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one improved CD4+ T cell responses as seen by increased expression of activation markers, improved proliferation and supported preferential TH1 differentiation. DUSP6 is a potential intervention target for restoring T cell responses in the elderly, which may augment the effectiveness of vaccination.

With increasing age, the ability of the human immune system to protect against new antigenic challenges or to control chronic infections declines1,2. More than 90% of all influenza-related deaths in the United States occur in the elderly3 where the mortality and morbidity with infections is high, and the response to vaccinations is diminished4,5.

There are many putative mechanisms that can explain age-related decrements in adaptive immunity. Declining thymic function has frequently been implicated68, but in spite of thymic demise, declines in naïve CD4+ T cell compartment sizes with age are subtle9. Moreover, TCR diversity within the naïve CD4+ T cell compartment in 60–65 year-old individuals is not different from that in 20–30 year-old individuals and the diversity only contracts late in life10,11. Thus, individuals maintain a diverse repertoire of naïve CD4+ T cells which should endow them with the competence to respond to antigenic challenges or vaccinations into their eighth decade of life.

In mice, an increasing lifespan of naïve CD4+ T cells with age has been associated with the emergence of functional defects12. TCR signaling is substantially and globally impaired, preferentially affecting the ability of naïve CD4+ T cells to produce interleukin (IL)-2. Human CD4+ naïve T cells are also affected by age, in particular homeostatic proliferation results in a substantial cumulative telomeric loss that impairs proliferative responses13,14. In contrast to mice, global age-dependent changes in human TCR signaling can generally be attributed to expanded effector cell populations that have lost CD27 and CD28 and gained numerous regulatory cell surface molecules15. Major signaling defects, such as the lack of calcium influx observed in mouse naïve CD4+ T cells, are not seen in humans and any signaling alterations are subtle and dependent on signal strength16.

Over the last decade, signal threshold calibration after TCR stimulation has been increasingly defined, and many settings have been identified where signal strength determines remarkably different functional outcomes, ranging from positive and negative selection in thymic development to recognition of agonistic and antagonistic peptides in peripheral T cells and differentiation into effector cell lineages17. Among the molecular components calibrating TCR-induced signal strength, feedback loops involving ERK activity play a critical role18. TCR threshold calibration is most evident in the differentiation from thymocytes that are selected on self-antigenic peptides, to mature T cells that are no longer responsive to self. Increased expression of several phosphatases including the dual specific phosphatases (DUSP)5 and 6 has been implicated in this loss of TCR sensitivity19,20. DUSPs represent a family of phosphatases that dephosphorylate phosphothreonine and phosphotyrosine residues on MAPK and that are pivotal regulators of MAPK activities21,22.

Here we report that naïve CD4+ T cells from elderly individuals have a reduced signaling potential of the ERK pathway. The underlying mechanism is an age-related decline in miR-181a expression and associated rise in levels of DUSP6. The higher levels of DUSP6 raise the threshold for productive T cell activation by dampening the initial ERK signal after TCR stimulation. Accordingly, lower fractions of naïve CD4+ T cells are activated in the elderly, in particular to low affinity stimuli. Our studies suggest that DUSP6 inhibition may be a potential intervention to improve T cell responses in the elderly.


Methods and any associated references are available in the online version of the paper at



We obtained peripheral blood from 357 individuals (aged 20–85 years). Subjects with acute diseases, current or previous history of immune-mediated diseases or cancer except limited basal cell carcinoma or chronic diseases not controlled on oral medications were excluded. In all experiments and for each age group, we included an approximate equal number of male and female subjects. The study was approved by the Emory and Stanford Institutional Review Boards, and all participants gave written informed consent. To isolate naïve CD4+ T cells from PBMC, memory T cells and CD14+ monocytes were depleted by anti-CD45RO and anti-CD14 magnetic microbeads (Miltenyi Biotec Inc.). CD4+ cells were then positively isolated. Purity was >95%. Memory CD4+ T cells were isolated by depleting PBMC of CD45RA+ and CD14+ cells followed by positive selection for CD4. In some experiments, CD4+ T cells were purified from whole blood or PBMC with a CD4+ T cell enrichment cocktail kit (STEMCELL Technologies Inc.) followed by positive selection of naïve T cells with anti-CD45RA magnetic microbeads. Dendritic cells (DCs) were generated from CD14+ monocytes by culture with 800 U ml−1 GM-CSF and 1,000 U ml−1 IL-4 (R&D Systems) for six days, and matured with 1,100 U ml−1 TNF-α (R&D Systems) and 1 µg ml−1 PGE2 (Sigma) for 24 h.

T cell–DC coculture

Naïve CD4+ T cells (25×103 cells) labeled with 5 µM carboxy-fluorescein diacetate succinimidyl ester (CFSE; Molecular Probes) were cultured with 0.5×103 DC and indicated concentration of toxic shock syndrome toxin 1 (TSST-1, Toxin Technology). Cell and TSST-1 concentrations were optimized to minimize alloreactive responses (Supplementary Fig. 1) and activate approximately 90% of Vβ2+ cells in young individuals. We determined the fraction of Vβ2+ or Vβ2 CD4+ naïve T cells that had divided on day 4 after stimulation. CD69 and CD25 expression in Vβ2+ CD4+ T cells was examined at 6, 12, 24, and 36 h postactivation by staining with anti-CD69 PE-Cy7 and anti-CD25-APC (all from BD Biosciences). In some experiments, we used CD4+ T cells transfected with miR-181a precursor or DUSP6 siRNA and determined proliferative response by 3H-thymidine incorporation and IL-2 production.

Signaling studies

T cells negatively isolated by Human T Cell Enrichment Cocktail (STEMCELL Technologies Inc.) were stimulated with anti-CD3 (1 µg ml−1) cross-linking or PMA (0.5 ng ml−1) at 37°C, fixed in BD Cytofix buffer, permeabilized by BD Perm Buffer III (for ERK and PLC-γ1) or II (for ZAP70), and stained with the following antibodies: anti-CD3-APC-Cy7, anti-CD4-PerCP, anti-CD8-PE, anti-CD45RA-PE-Cy7, and Alexa Fluor 647-conjugated anti-phospho-ERK1/2 (pT202/pY204), anti-phospho-ZAP70 (pY319)/SYK (pY352) or anti-phospho-PLC-γ1 (pY783) (all from BD Biosciences). Phosphorylation was analyzed on an LSRII flow cytometer (BD Biosciences) with FACS Diva software.

Real-time polymerase chain reaction

We quantified DUSP6, SHP-2, PTPN22, c-Myc and Cyclin D1 transcripts by SYBR qPCR using the following primers: DUSP6: 5'-CAGTGGTGCTCTACGACGAG-3' and 5'-GCAATGCAGGGAGAACTCGGC; SHP-2: 5'-GAAGTGGAGAGAGGAAAGAG-3' and 5'-GTCCGAAAGTGGTATTGCCAGA-3'; PTPN22: 5'-TTCTCTGTATCCTGTGAAGCTG-3' and 5'-CTGTCATCCTCTTGGTAACAACGT-3'; c-Myc: 5'-GCAGGGCTTCTCAGAGGCTTG-3' and 5'-GCCTCTCGCTGGAATTACTACAG-3'; Cyclin D1: 5'-ACTTGCATGTTCGTGGCTTCT-3' and 5'-CTTCACATCTGTGGCACAGAG-3'; β-actin: 5'-ATGGCCACGGCTGCTTCCAGC-3' and 5'-CATGGTGGTGCCGCCAGACAG-3'; 18s rRNA: 5'-GTTGAACCCCATTCGTGATG-3' and 5'-GCCTCACTAAACCATCCAA-3'. Transcript numbers were normalized to β-actin (for DUSP6, SHP-2 and PTPN22) or 18s rRNA (for c-Myc and Cyclin D1) transcripts.

Western blotting

We lysed purified total CD4+naïve CD4+ and memory CD4+ T cells in lysis buffer (Cell Signaling Technology, Inc.). Samples were electrophoresed on a 10% sodium dodecyl sulfate-polyacrylamide gel and transferred to a nitrocellulose membrane. Blots were probed with antibody to DUSP6 (Santa Cruz Biotechnology, Inc.), antibody to PTPN22 (gift from Dr. A. C. Chan, Genentech, Inc.) and antibody to SHP-2 (Cell Signaling Technology, Inc). In additional experiments (e.g. Supplementary Figs. 3 and 4), an antibody to DUSP6 from OriGene Technologies, Inc. was used. Membranes were developed with horseradish peroxidase-labeled secondary antibody (Santa Cruz Biotechnology, Inc.) and Immobilon Western chemiluminescence detection system (Millipore).

miRNA quantification

We assayed miR-181a and miR-142 expression levels using a mirVana™ qRT-PCR miRNA detection kit (Applied Biosystems). Briefly, 25 ng of RNA from isolated T cells was reverse-transcribed in 10 µl at 37°C for 30 min using a miRNA- or U6-specific oligonucleotide. miRNAs were then quantified by SYBR qPCR in 25 µl under the following conditions: 95°C for 3 min followed by 40 cycles of 95°C for 15 s, 60°C for 30 s.


To overexpress or silence miR-181a, we transfected total or CD4+ T cells with miR-181a precursor or negative control (Applied Biosystems); miR-181a inhibitor or miRNA inhibitor negative control (Thermo Fisher Scientific) using Nucleofector® Kit (Amaxa, Lonza Walkersville, Inc.). To silence DUSP6 expression, we transfected CD4+ T cells with SMARTpool DUSP6 (3 µg) or negative control siRNA (Thermo Fisher Scientific). SMARTpool DUSP6 siRNA included the sequences 5'-GAACUGUGGUGUCUUGGUA-3', 5'-UGGCUUACCUUAUGCAGAA-3', 5'-GACUGUGGCUUACCUUAUG-3' and 5'-GCGACUGGAACGAGAAUAC-3'. DUSP6 silencing effects were confirmed by a second DUSP6 siRNA (5'-UGCAUAUAGAGGAGCCAAAGAGAGA-3', OriGene Technologies). Forty-eight hours after transfection, cells were harvested; DUSP6 transcription and protein expression were quantified, and cells were assayed for their response to CD3/CD28 cross-linking or stimulation with mDC and TSST-1. To force overexpression of DUSP6 in CD4+ T cells, DUSP6 cDNA was inserted into vector pIRES2-AcGFP1 (Clontech Laboratories, Inc.). Four micrograms of the pIRES2-DUSP6 or the empty control plasmid were used for each transfection.

DUSP6 inhibition

PBMC were incubated with the DUSP6 inhibitor (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI) at 37°C for 1 h. Cells were washed three times and then stimulated by cross-linking with anti-CD3/CD28 antibody (1 µg ml−1). After 24 h, cells were harvested and CD69, CD25 and IL-2 expression were analyzed on an LSRII flow cytometer.

T cell differentiation

CD4+ naïve T cells were transfected with DUSP6 (3 µg) or negative control siRNA. Forty-eight hours after transfection, cells were stimulated with plate-bound anti-CD3 (1 µg ml−1) and anti-CD28 antibody (1 µg ml−1) alone (nonpolarizing control) or in the presence of IL-12 (20 ng ml−1PeproTech, Inc.) and IL-4−neutralizing antibody (10 µg ml−1) for TH1 or IL-4 (25 ng ml−1) and anti-IFN-γ antibody (10 µg ml−1) (all from R &D Systems) for TH2 polarization. Cells were collected on day 7, stimulated with PMA (50 ng ml−1Sigma) and ionomycin (500 ng ml−1Sigma) in the presence of brefeldin for 5 h, and analyzed for cytokine production using anti-CD4-PerCP, anti-IFN-γ-FITC and anti-IL-4-PE (all from BD Biosciences).

Statistical analysis

Statistical comparisons were performed by two-way ANOVA using SigmaStat 3.0 software. Age, DUSP6 and miR-181a expression were compared by Pearson’s correlation. DUSP6 inhibition experiments with BCI were analyzed by repeated measure ANOVA. TCR-induced expression of activation markers and gene expression after miR-181a overexpression were compared by paired t test.


Decreased sensitivity to T cell receptor stimulation with age

The frequency of naïve CD4+ T cells changes with age but this decline does not fully explain the defective T cell response suggesting T cell intrinsic defects. We probed T cell function under relatively physiological conditions by stimulating purified naïve CD4+ T cells from healthy individuals of different age groups with the superantigen toxic shock syndrome toxin (TSST)-1 presented by myeloid dendritic cells (mDCs) from young adults (Supplementary Fig. 1). TSST-1 is known to stimulate all Vβ2+ and a small fraction of Vβ2 T cells, the latter only at higher concentrations suggesting lower affinity. The number of dendritic cells (DCs) in the system was adjusted so that an alloreactive response in the absence of TSST-1 was not detectable. In initial kinetic experiments, we determined the fraction of Vβ2+ naïve CD4+ T cells that were stimulated to express CD69 and CD25. Expression of these activation markers in elderly naïve CD4+ T cells was delayed, suggesting that longer stimulation is needed for elderly T cells to build up the required signaling strength (Fig. 1a). To examine this possibility in more detail, we determined the fraction of naïve CD4+ T cells that were activated in eleven 20–35 year-old and eleven 70–85 year-old individuals using decreasing doses of superantigen (Fig. 1b). At high doses, approximately 90% of Vβ2+ T cells entered proliferation independent of age. With decreasing doses, a difference became apparent. Dose-response curves were shifted for the elderly towards higher doses of antigen by a factor of approximately ten. In subsequent experiments with naïve CD4+ T cells from thirty-five 20–35 and seventeen 70–85 year-old individuals at a low TSST-1 concentration of 0.04 ng ml−1a significantly lower number of naïve CD4+ T cells responded to stimulation in the elderly individuals (Fig. 1c). The difference was more pronounced for Vβ2 naïve CD4+ T cells (P < 0.0001) than for Vβ2+ cells (P = 0.002). Taken together, these data suggest that TCR activation thresholds are increased in naïve CD4+ T cells from elderly individuals, and productive activation requires higher antigen doses or higher affinity antigens.

Figure 1
Decreased sensitivity of naïve CD4+ T cells to respond to antigenic stimulation with age

Age-associated T cell receptor signaling defects

To probe early signaling events after TCR stimulation, we used phospho-epitope analysis by flow cytometry. CD3 cross-linking induced equal phosphorylation of ZAP70 when naïve and memory CD4+ T cells from fifteen 20–35 year-old and fifteen 70–85 year-old adults were compared, suggesting that initial signaling is intact and not affected by age (Fig. 1d). Also, PLC-γ1 phosphorylation which is just upstream of IP3 generation and calcium flux was not age-dependent (Fig. 1d) documenting that human T cells do not exhibit the signature of defective calcium signaling that is characteristic for immune aging in mice23. In contrast, naïve CD4+ T cells from young adults were significantly more effective in phosphorylating ERK; results from 20 young and 20 old individuals are shown (P < 0.0001, Fig. 1d). A similar difference in ERK phosphorylation was not seen for memory CD4+ T cells. Studies examining PMA-induced ERK phosphorylation indicated that the defect affects the ERK pathway distal of Ras/Raf activation. ERK phosphorylation due to PMA-induced PI3-kinase activation was significantly different between the two age groups (Fig. 1e).

Age-associated overexpression of DUSP6

One major feedback loop that controls the activation of the ERK pathway in T cells and that attenuates TCR signaling involves DUSP6, a cytoplasmic phosphatase with substrate specificity for phosphorylated ERK. Increased Dusp6 protein expression during T cell development has been implicated in the reduced sensitivity of mature mouse T cells to respond to self-antigens compared to thymocytes19. Given the selective decrease in TCR-induced ERK activation, we explored whether human expression levels of DUSP6 increase with aging. DUSP6 was more abundant in CD4+ T cells from 70–85 year-old adults compared to young adults as determined by Western blots (Fig. 2a, P = 0.01). This increase was entirely due to the naïve CD4+ population (P = 0.008); we did not see a difference for memory CD4+ T cells (Fig. 2b). To determine the relationship between age and DUSP6 expression in more detail, we examined naïve and memory CD4+ T cells from 60 additional individuals with similar numbers of individuals for each age decade between 20 and 80 years. DUSP6 protein expression in naïve CD4+ T cells linearly increased throughout the entire age range (r = 0.68, P < 0.0001, Fig. 2c, left panel), while it did not exhibit a significant age dependency in CD4+ memory T cells (r = 0.25, n.s., Fig. 2c, right panel).

Figure 2
Age-associated expression of DUSP6

Loss in miR-181a accounts for increased DUSP6 expression

Increased DUSP6 protein expression with age was not reflected at the transcript level. DUSP6 transcript numbers in total CD4+ T cells from twenty 20–35 and twenty 70–85 year-old individuals were similar as determined by qPCR (Fig. 3a). Memory CD4+ T cells tended to have lower transcript levels than naïve CD4+ T cells, both in the young and the old (Fig. 3a, right). In mouse studies by Li et al, Dusp6 was one of several phosphatases controlled by miR-181a19. We therefore determined whether expression of miR-181a in CD4+ T cells change with age. Comparison of CD4+ T cells from twenty-one 20–35 and twenty-one 70–85 year-old individuals showed a threefold decline (Fig. 3b, P = 0.0005) which was mostly attributable to the naïve population (Fig. 3c, P = 0.0008). Memory CD4+ T cells have lower miR-181a than naïve CD4+ T cells in the young (P = 0.004) and only show a small further decrease with age. In contrast, miR-142, examined as a system control, did not change with age (Fig. 3b). The decline in miR-181a expression in naïve CD4+ T cells is progressive throughout adult life. miR-181a expression was assessed in a cohort of 58 individuals, in part overlapping with those shown in Fig. 3c. Levels declined in naïve (Fig. 3d, left panel, r = −0.59, P < 0.0001), but only insignificantly in memory CD4+ T cells (Fig. 3d, right panel, r = −0.19, P = 0.36).

Figure 3
Age-associated expression of miR-181a

Comparison of miR-181a and DUSP6 protein expression yielded a significant negative correlation (Fig. 4a, r = −0.51, P < 0.0001) that was only partially explained by their age associations. When adjusted for age, correlations were maintained for young (23–37 years) and middle-aged (37–55 years) adults supporting the notion that miR-181a is an important regulator of human DUSP6 as originally described in the mouse system. We did not find a correlation for individuals older than 55 years, possibly indicating that miR-181a were too low to influence DUSP6 expression (Fig. 4b). To confirm whether the decrease in miR-181a is responsible for increased DUSP6 expression, we transfected CD4+ T cells from elderly individuals with miR-181a precursor and determined DUSP6 protein expression by Western blot. A representative experiment shows a reduced DUSP6 band intensity in CD4+ T cells that were transfected with miR-181a precursor (Fig. 4c). Importantly, elderly CD4+ T cells transfected with the miR-181a precursor expressed increased activation markers after CD3 stimulation compared to control-transfected T cells. An increased IL-2 production by restoring miR-181a levels was reversed by parallel forced overexpression of DUSP6 (Fig. 4d). Activation-induced expression of CD69 was enhanced by either increasing miR-181a or silencing DUSP6. Double transfection with DUSP6 siRNA and miR-181a precursor only facilitated a small additional increase in CD69 expression (Fig. 4e). Conversely, miR-181a silencing reduced activation-induced CD69 expression compared to control-transfected cells (Fig. 4f). Co-transfection with DUSP6 siRNA reversed the effect of transfection with miR-181a inhibitor alone. In summary, these experiments are consistent with the interpretation that miR-181a regulates human TCR threshold by controlling DUSP6 expression. The minor synergistic action between DUSP6 silencing and miR-181a overexpression is likely due to incomplete silencing in the single transfected cells. Furthermore, PTPN22 and SHP-2, which are also targeted by miR-181a in the mouse, were not influenced by age in human T cells (Fig. 4g). The effect of miR-181a on DUSP5, which is also regulated by miR-181a in the mouse, was undetermined because the expression levels in human T cells were too low to be detected with the available antibody (data not shown).

Figure 4
miR-181a controls DUSP6 expression

Increased miR-181a expression restores T cell responses in the elderly

To determine whether restoration of miR-181a levels improves T cell activation in the elderly, T cells from eleven 20–35 and eleven 70–85 year-old individuals were transfected with miR-181a precursor or miRNA precursor negative control. ERK phosphorylation after anti-CD3 cross-linking was determined in gated naïve and memory CD4+ T cells by PhosphoFlow (Fig. 5a). Consistent with the data shown in Figure 1, activation-induced ERK phosphorylation was reduced in elderly naïve, but not memory CD4+ T cells. Overexpression of miR-181a improved the ERK response significantly in elderly naïve CD4+ T cells (P = 0.002) to approximately the same response level that is seen in the young adult. A lesser increase was seen in naïve CD4+ T cells from young adults which still reached significance (P = 0.03). In contrast, the ERK response in CD4+ memory T cells was not influenced by miR-181a overexpression in the young adult and only slightly improved in the elderly. Increased ERK responses were functionally important. Upon TCR stimulation, T cells from elderly individuals expressed increased transcript numbers of c-Myc (P = 0.008) and Cyclin D1 (P = 0.01) when transfected with miR-181a (Fig. 5b). In parallel, activation-induced expression of IL-2 (P = 0.02) and CD25 (P = 0.004) in naïve CD4+ T cells improved (Fig. 5c). Also, miR181a overexpression augmented proliferative responses to CD3 cross-linking (Fig. 5d) and stimulation with DC and TSST-1 (Fig. 5e).

Figure 5
miR-181a overexpression restores T cell activities in elderly CD4+ T cells

DUSP6 inhibition augments T cell activation

Given that increased expression of DUSP6 is the major consequence of miR-181a loss in elderly human CD4+ T cells, inhibition of DUSP6 may be sufficient to restore CD4+ T cell activation. When CD4+ T cells were transfected with DUSP6 siRNA, a decline in protein expression was evident after 48 h (Fig. 6a); similar results were observed with two different siRNA sequences. Transfected CD4+ T cells from 60–80 year-old individuals were maintained for 48 h and then stimulated under suboptimal condition with anti-CD3/CD28 antibodies. Silencing of DUSP6 increased induction of CD69 (P < 0.0001), CD25 (P < 0.0001) and IL-2 (P < 0.0001) (Fig. 6b). Increased IL-2 production by silencing of endogenous DUSP6 was overcome by forced overexpression of DUSP6 (Fig. 6c). DUSP6 silencing also increased proliferative responses, in particular at low concentrations of stimulating anti-CD3 monoclonal antibody (Fig. 6d) or to stimulation with TSST-1 and DC (Fig. 6e). Similar results were found with the second DUSP6 siRNA (Supplementary Fig. 5). With optimal doses of anti-CD3 monoclonal antibody, proliferative responses in DUSP6-silenced and control T cells reached the same plateau consistent with the interpretation in Figure 1 that low affinity antigen responses were more affected in the elderly.

Figure 6
DUSP 6 inhibition augments activation of elderly CD4+ T cells

Initial TCR signal strength not only determines whether a T cell is activated or not, but also has lasting effects on T cell differentiation. High signal strength favors a TH1, and low signal strength a TH2 response. To determine whether DUSP6 activity influences T cell polarization, naïve CD4+ T cells transfected with DUSP6 siRNA were activated and cultured under TH1 and TH2 polarizing conditions. DUSP6 silencing supported the induction of a TH1 response (P = 0.003) while disfavoring the differentiation into TH2 cells (P = 0.0006) compared to control transfected T cells (Fig. 6f).

These results support the notion that DUSP6 is a suitable pharmacological target to improve naïve CD4+ T cell responses, in particular in the elderly. (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI) has been shown to be an inhibitor of DUSP6 activity24. As BCI binds to an allosteric site and not the catalytic phosphatase domain, its cross-reactivity is limited. We stimulated peripheral blood mononuclear cells (PBMC) from ten 60–85 year-old individuals under suboptimal conditions with anti-CD3/CD28 antibodies in the presence of increasing concentrations of BCI. CD69 and CD25 mean fluorescent intensity (MFI) were quantified as markers of T cell activation. BCI enhanced induction of CD69 expression on naïve (P < 0.0001) (Fig. 6g, left panel) in a dose-dependent manner. BCI treatment also enhanced CD25 expression (middle panel) and IL-2 production in naïve CD4+ T cells (right panel).


Our studies demonstrate that naïve CD4+ T cells lose TCR sensitivity and signaling strength with age due to reduced expression of miR-181a. Since miR-181a represses DUSP6, DUSP6 protein concentrations increase with age dampening ERK activation. ERK activity is a pivotal regulator of TCR threshold calibration by controlling positive feedback loops in the TCR-induced activation cascade; reduced ERK activity impairs signal strength and activation of individual T cells. Moreover, due to an increased TCR threshold setting, only T cells with higher affinity to antigen are activated leading to a contracted immune response to a given antigenic peptide. Inhibition of DUSP6 emerges as a key intervention to strengthen and broaden naïve CD4+ T cell responses in the elderly.

Declining regenerative capacity with age and inability to maintain a balance between functional T cell subsets and a diverse TCR repertoire have been held responsible for the deteriorating adaptive immune response11,25,26. Indeed, homeostasis of CD8+ T cells is not well maintained with age, naïve and central memory CD8+ T cells are lost while terminally differentiated effector T cells accumulate, and clonal CD8+ T cell expansion dominates the repertoire9,27. CD8+ T cell oligoclonality and senescence correlate with poor vaccine responses and general mortality and may account for the prolonged viremia in elderly patients infected with influenza2830. In contrast, CD4+ T cell homeostasis is better maintained over life31. In spite of thymic demise in mid-adulthood, compartment sizes of naïve and central memory CD4+ T cells are substantial, and expansion of the CD28 CD4+ T cell population is infrequent and usually related to disease15. Nevertheless, adaptive immune responses that rely on CD4+ T cell function, such as the production of antibodies after vaccination, are impaired with age4.

While signaling studies in mouse systems have been very successful to define age-related defects32, including a defect in the ERK pathway33, initial findings with human T cells34,35 have not been further studied and defects are not well characterized, in part because human age-related defects are more variable and subtle and are difficult to quantify, given the changes in T cell subset distributions with age. Also, transcription of signaling molecules involved in TCR signaling does not appear to be influenced by age36. In the present study we demonstrate a selective dampening of the ERK signaling pathway. This defect was seen in naïve CD4+ T cells and did not involve naïve or memory CD8+ T cells (unpublished observation) or memory CD4+ T cells. The underlying mechanism is a loss in miR-181a and therefore not obvious in transcriptional studies.

The concept that a miRNA expression level acts as a rheostat that controls TCR signaling and accounts for different TCR sensitivities at different developmental stages has been introduced by Li et al19. Immature T cell precursor populations such as double-positive thymocytes undergoing selection by the recognition of self-antigen express high levels of miR-181a. The inhibition of this miRNA impairs positive and negative selection. In contrast, mature TH1 and TH2 cells expressed low levels of miR-181a decreasing TCR sensitivity. Overexpressing miR-181a increased signaling strength and facilitated responses to partially agonistic or antagonistic peptides. In consensus with these mouse studies, we found a higher expression of miR-181a in naïve CD4+ T cells from young adults compared to memory CD4+ T cells. Cumulative homeostatic proliferation may have induced a similar loss of miR-181a with age in naïve cells as with T cell differentiation. This loss appears to be rather selective because no other features of memory T cells are observed in elderly phenotypically naïve CD4+ T cells. These cells express CD28, CD27 and CCR7 and have a diverse TCR repertoire setting them apart from memory T cells11,37.

In the mouse, miR-181a modulated TCR sensitivity by inhibiting the protein expression of several phosphatases including Dusp5, Dusp6, SHP-2 and PTPN2219. In human CD4+ T cells, only an upregulation of DUSP6 with age was found. Consistent with this finding, forced overexpression of DUSP6 in elderly T cells reversed the improved T cell responsiveness obtained from increasing miR-181a expression. The relative selectivity in humans for this one phosphatase involved in TCR threshold calibration holds the promise that DUSP6 inhibition will significantly improve the immune response in the elderly. A small-molecule DUSP6 inhibitor has recently been described24 and experiments indeed document that this inhibitor improves responses of elderly T cells in vitro (Fig. 6g).

The increased susceptibility of the elderly to infection represents a major public health problem. Preventive measures by vaccinations are of critical importance; however, so far they have had only a moderate impact because of reduced immune responsiveness38. Improving vaccine responses to overcome age-related immune defects is a challenge but also represents a unique opportunity to attain healthy aging. Approaches have mainly targeted antigen presentation by increasing antigen dose or by using adjuvant. Influenza vaccination using an oil-in-water emulsion adjuvant, MF59, has yielded increased induction of protective antibodies3941. Increasing dosage of of influenza and varicella zoster vaccines42,43 have improved clinical efficacy consistent with the interpretation that elderly T cells have an increased threshold to respond that can be overcome by increased antigen doses. Our studies suggest that, in addition to enhancing the vaccine, T cells can be directly targeted to improve responsiveness by lowering the TCR activation threshold and modifying early TCR signaling.

Supplementary Material


J.J.G. was supported by US National Institutes of Health grants U19 AI090019, R01 AG015043, U19 AI057266, and C.M.W. by US National Institutes of Health grants R01 AR042527, R01 EY011916, R01 AI044142, and PO1 HL058000.



GL, MY, WL, CMV and JJG designed experiments and analyzed data. GL, MY and WL generated data. MT provided BCI and advice in the design of the DUSP6 inhibition experiments. EK recruited and clinically phenotyped healthy elderly individuals. GL and JJG wrote the manuscript.


The authors declare no competing financial interests.


1. Weng NP. Aging of the immune system: how much can the adaptive immune system adapt? Immunity. 2006;24:495–499. [PMC free article] [PubMed]
2. Hakim FT, Gress RE. Immunosenescence: deficits in adaptive immunity in the elderly. Tissue Antigens. 2007;70:179–189. [PubMed]
3. Thompson WW, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–186. [PubMed]
4. Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine. 2007;25:3066–3069. [PubMed]
5. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med. 2007;357:1373–1381. [PubMed]
6. Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat. Rev. Immunol. 2004;4:123–132. [PubMed]
7. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu. Rev. Immunol. 2000;18:529–560. [PubMed]
8. Sauce D, et al. Evidence of premature immune aging in patients thymectomized during early childhood. J. Clin. Invest. 2009;119:3070–3078. [PMC free article] [PubMed]
9. Czesnikiewicz-Guzik M, et al. T cell subset-specific susceptibility to aging. Clin. Immunol. 2008;127:107–118. [PMC free article] [PubMed]
10. Naylor K, et al. The influence of age on T cell generation and TCR diversity. J. Immunol. 2005;174:7446–7452. [PubMed]
11. Goronzy JJ, Weyand CM. T cell development and receptor diversity during aging. Curr. Opin. Immunol. 2005;17:468–475. [PubMed]
12. Tsukamoto H, et al. Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects. Proc. Natl. Acad. Sci. U S A. 2009;106:18333–18338. [PubMed]
13. Macallan DC, et al. Rapid turnover of effector-memory CD4(+) T cells in healthy humans. J. Exp. Med. 2004;200:255–260. [PMC free article] [PubMed]
14. Hodes RJ, Hathcock KS, Weng NP. Telomeres in T and B cells. Nat. Rev. Immunol. 2002;2:699–706. [PubMed]
15. Weng NP, Akbar AN, Goronzy J. CD28(−) T cells: their role in the age-associated decline of immune function. Trends Immunol. 2009;30:306–312. [PMC free article] [PubMed]
16. Goronzy JJ, Li G, Yu M, Weyand CM. Signaling pathways in aged T cells - A reflection of T cell differentiation, cell senescence and host environment. Sem. Immunol. 2012 In press. [PMC free article] [PubMed]
17. Berg LJ. Strength of T cell receptor signaling strikes again. Immunity. 2009;31:529–531. [PubMed]
18. Altan-Bonnet G, Germain RN. Modeling T cell antigen discrimination based on feedback control of digital ERK responses. PLoS Biol. 2005;3:e356. [PubMed]
19. Li QJ, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007;129:147–161. [PubMed]
20. Bettini ML, Kersh GJ. MAP kinase phosphatase activity sets the threshold for thymocyte positive selection. Proc. Natl. Acad. Sci. U S A. 2007;104:16257–16262. [PubMed]
21. Guan KL, Butch E. Isolation and characterization of a novel dual specific phosphatase, HVH2, which selectively dephosphorylates the mitogen-activated protein kinase. J. Biol. Chem. 1995;270:7197–7203. [PubMed]
22. Zhang Y, et al. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature. 2004;430:793–797. [PubMed]
23. Miller RA, Garcia G, Kirk CJ, Witkowski JM. Early activation defects in T lymphocytes from aged mice. Immunol. Rev. 1997;160:79–90. [PubMed]
24. Molina G, et al. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat. Chem. Biol. 2009;5:680–687. [PMC free article] [PubMed]
25. Yager EJ, et al. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med. 2008;205:711–723. [PMC free article] [PubMed]
26. Cicin-Sain L, et al. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates. J. Immunol. 2010;184:6739–6745. [PMC free article] [PubMed]
27. Clambey ET, van Dyk LF, Kappler JW, Marrack P. Non-malignant clonal expansions of CD8+ memory T cells in aged individuals. Immunol. Rev. 2005;205:170–189. [PubMed]
28. Messaoudi I, Lemaoult J, Guevara-Patino JA, Metzner BM, Nikolich-Zugich J. Age-related CD8 T cell clonal expansions constrict CD8 T cell repertoire and have the potential to impair immune defense. J. Exp. Med. 2004;200:1347–1358. [PMC free article] [PubMed]
29. Saurwein-Teissl M, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J. Immunol. 2002;168:5893–5899. [PubMed]
30. Goronzy JJ, et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol. 2001;75:12182–12187. [PMC free article] [PubMed]
31. Goronzy JJ, Lee WW, Weyand CM. Aging and T-cell diversity. Exp. Gerontol. 2007;42:400–406. [PMC free article] [PubMed]
32. Sadighi Akha AA, Miller RA. Signal transduction in the aging immune system. Curr. Opin. Immunol. 2005;17:486–491. [PubMed]
33. Gorgas G, Butch ER, Guan KL, Miller RA. Diminished activation of the MAP kinase pathway in CD3-stimulated T lymphocytes from old mice. Mech. Ageing Dev. 1997;94:71–83. [PubMed]
34. Ledbetter JA, et al. Signal transduction through CD4 receptors: stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor. Eur. J. Immunol. 1988;18:525–532. [PubMed]
35. Grossmann A, Ledbetter JA, Rabinovitch PS. Reduced proliferation in T lymphocytes in aged humans is predominantly in the CD8+ subset, and is unrelated to defects in transmembrane signaling which are predominantly in the CD4+ subset. Exp. Cell Res. 1989;180:367–382. [PubMed]
36. Lee WW, et al. Age-dependent signature of metallothionein expression in primary CD4 T cell responses is due to sustained zinc signaling. Rejuvenation Res. 2008;11:1001–1011. [PMC free article] [PubMed]
37. Boyman O, Letourneau S, Krieg C, Sprent J. Homeostatic proliferation and survival of naive and memory T cells. Eur. J. Immunol. 2009;39:2088–2094. [PubMed]
38. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun. Ageing. 2007;4:9. [PMC free article] [PubMed]
39. Khurana S, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2010;2:15ra15. [PubMed]
40. Del Giudice G, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine. 2006;24:3063–3065. [PubMed]
41. Galli G, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. U S A. 2009;106:3877–3882. [PubMed]
42. Couch RB, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine. 2007;25:7656–7663. [PMC free article] [PubMed]
43. Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 2005;352:2271–2284. [PubMed]